Hinge Health, Inc. Class A (HNGE) Stock Forecast & Price Target

Compare

170 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

HNGE Analyst Ratings

Strong Buy

14 Buy

0 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Hinge

Health, Inc. Class A

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

HNGE Stock 12 Month Forecast

Average Price Target

$59.08

▲(38.17% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Hinge Health, Inc. Class A in the last 3 months. The average price target is $59.08 with a high forecast of $72.00 and a low forecast of $50.00. The average price target represents a 38.17% change from the last price of $42.76.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"34":"$34","73":"$73","43.75":"$43.8","53.5":"$53.5","63.25":"$63.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":72,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$72.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":59.08,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$59.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$50.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[34,43.75,53.5,63.25,73],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.23,38.058461538461536,40.886923076923075,43.715384615384615,46.543846153846154,49.37230769230769,52.200769230769225,55.029230769230765,57.857692307692304,60.68615384615384,63.51461538461538,66.34307692307692,69.17153846153846,{"y":72,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.23,37.06461538461538,38.89923076923077,40.73384615384615,42.568461538461534,44.403076923076924,46.237692307692306,48.07230769230769,49.90692307692308,51.74153846153846,53.576153846153844,55.41076923076923,57.245384615384616,{"y":59.08,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.23,36.36615384615384,37.50230769230769,38.638461538461534,39.77461538461538,40.910769230769226,42.04692307692307,43.183076923076925,44.31923076923077,45.45538461538462,46.59153846153846,47.72769230769231,48.863846153846154,{"y":50,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":40.16,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":40.16,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":40.16,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":40.16,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.45,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.31,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.68,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.75,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.76,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.96,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.45,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.23,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$72.00

Average Price Target$59.08

Lowest Price Target$50.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Grossman

Stifel Nicolaus

$59

Buy

37.98%

Upside

Reiterated

02/27/26

Stifel Nicolaus Sticks to Their Buy Rating for Hinge Health, Inc. Class A (HNGE)

Jailendra Singh

Truist Financial

―

Buy

―

Reiterated

02/12/26

Analysts Are Bullish on These Healthcare Stocks: QuidelOrtho (QDEL), Atossa Therapeutics (ATOS)

Richard Close

Canaccord Genuity

$65→$53

Buy

23.95%

Upside

Reiterated

02/11/26

Hinge Health price target lowered to $53 from $65 at CanaccordHinge Health price target lowered to $53 from $65 at Canaccord

Craig Hettenbach

Morgan Stanley

$72

Buy

68.38%

Upside

Reiterated

02/11/26

Morgan Stanley Keeps Their Buy Rating on Hinge Health, Inc. Class A (HNGE)

Elizabeth Anderson CFA

Evercore ISI

$65→$50

Buy

16.93%

Upside

Reiterated

02/11/26

Hinge Health price target lowered to $50 from $65 at Evercore ISIHinge Health price target lowered to $50 from $65 at Evercore ISI

Scott Schoenhaus

KeyBanc

$70→$55

Buy

28.62%

Upside

Reiterated

02/11/26

Hinge Health price target lowered to $55 from $70 at KeyBancHinge Health price target lowered to $55 from $70 at KeyBanc

Ryan MacDonald

Needham

$59

Buy

37.98%

Upside

Reiterated

02/11/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Bradley Sills

Bank of America Securities

$64

Buy

49.67%

Upside

Reiterated

02/10/26

Buy Rating on Hinge Health, Inc. Class A Driven by Strong Q4 Outperformance, Margin Expansion, and Multi‑Year Growth Outlook

Ryan Daniels

William Blair

―

Buy

―

Reiterated

02/10/26

Hinge Health: Strong Beat, Operating Leverage, and Cash Generation Create an Attractive Long‑Term Buy After Share Pullback

Rishi Jaluria

RBC Capital

$60→$50

Buy

16.93%

Upside

Reiterated

02/10/26

RBC Capital Sticks to Its Buy Rating for Hinge Health, Inc. Class A (HNGE)

Saket Kalia

Barclays

$60

Buy

40.32%

Upside

Reiterated

02/09/26

Analysts Are Bullish on Top Healthcare Stocks: Hinge Health, Inc. Class A (HNGE), Centene (CNC)

Eugene Mannheimer

Freedom Capital Markets

$59

Buy

37.98%

Upside

Initiated

01/22/26

Hinge Health, Inc. Class A (HNGE) Has a New Rating from Freedom Capital Markets

Jessica Tassan

Piper Sandler

$71→$60

Buy

40.32%

Upside

Reiterated

01/09/26

Hinge Health price target lowered to $60 from $71 at Piper SandlerHinge Health price target lowered to $60 from $71 at Piper Sandler

Stan Berenshteyn

Wells Fargo

$68

Buy

59.03%

Upside

Initiated

01/09/26

Hinge Health initiated with an Overweight at Wells FargoHinge Health initiated with an Overweight at Wells Fargo

Aaron Kimson

Citizens JMP

$65

Buy

52.01%

Upside

Reiterated

10/31/25

Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (NYSE: HNGE), Bicycle Therapeutics (NASDAQ: BCYC) and Foghorn Therapeutics (NASDAQ: FHTX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Grossman

Stifel Nicolaus

$59

Buy

37.98%

Upside

Reiterated

02/27/26

Stifel Nicolaus Sticks to Their Buy Rating for Hinge Health, Inc. Class A (HNGE)

Jailendra Singh

Truist Financial

―

Buy

―

Reiterated

02/12/26

Analysts Are Bullish on These Healthcare Stocks: QuidelOrtho (QDEL), Atossa Therapeutics (ATOS)

Richard Close

Canaccord Genuity

$65→$53

Buy

23.95%

Upside

Reiterated

02/11/26

Hinge Health price target lowered to $53 from $65 at CanaccordHinge Health price target lowered to $53 from $65 at Canaccord

Craig Hettenbach

Morgan Stanley

$72

Buy

68.38%

Upside

Reiterated

02/11/26

Morgan Stanley Keeps Their Buy Rating on Hinge Health, Inc. Class A (HNGE)

Elizabeth Anderson CFA

Evercore ISI

$65→$50

Buy

16.93%

Upside

Reiterated

02/11/26

Hinge Health price target lowered to $50 from $65 at Evercore ISIHinge Health price target lowered to $50 from $65 at Evercore ISI

Scott Schoenhaus

KeyBanc

$70→$55

Buy

28.62%

Upside

Reiterated

02/11/26

Hinge Health price target lowered to $55 from $70 at KeyBancHinge Health price target lowered to $55 from $70 at KeyBanc

Ryan MacDonald

Needham

$59

Buy

37.98%

Upside

Reiterated

02/11/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Bradley Sills

Bank of America Securities

$64

Buy

49.67%

Upside

Reiterated

02/10/26

Buy Rating on Hinge Health, Inc. Class A Driven by Strong Q4 Outperformance, Margin Expansion, and Multi‑Year Growth Outlook

Ryan Daniels

William Blair

―

Buy

―

Reiterated

02/10/26

Hinge Health: Strong Beat, Operating Leverage, and Cash Generation Create an Attractive Long‑Term Buy After Share Pullback

Rishi Jaluria

RBC Capital

$60→$50

Buy

16.93%

Upside

Reiterated

02/10/26

RBC Capital Sticks to Its Buy Rating for Hinge Health, Inc. Class A (HNGE)

Saket Kalia

Barclays

$60

Buy

40.32%

Upside

Reiterated

02/09/26

Analysts Are Bullish on Top Healthcare Stocks: Hinge Health, Inc. Class A (HNGE), Centene (CNC)

Eugene Mannheimer

Freedom Capital Markets

$59

Buy

37.98%

Upside

Initiated

01/22/26

Hinge Health, Inc. Class A (HNGE) Has a New Rating from Freedom Capital Markets

Jessica Tassan

Piper Sandler

$71→$60

Buy

40.32%

Upside

Reiterated

01/09/26

Hinge Health price target lowered to $60 from $71 at Piper SandlerHinge Health price target lowered to $60 from $71 at Piper Sandler

Stan Berenshteyn

Wells Fargo

$68

Buy

59.03%

Upside

Initiated

01/09/26

Hinge Health initiated with an Overweight at Wells FargoHinge Health initiated with an Overweight at Wells Fargo

Aaron Kimson

Citizens JMP

$65

Buy

52.01%

Upside

Reiterated

10/31/25

Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (NYSE: HNGE), Bicycle Therapeutics (NASDAQ: BCYC) and Foghorn Therapeutics (NASDAQ: FHTX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Hinge Health, Inc. Class A

3 Months

xxx

Success Rate

4/6 ratings generated profit

Average Return

+8.90%

reiterated a xxx

rating 23 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +8.90% per trade.

1 Year

Ryan DanielsWilliam Blair

Success Rate

2/5 ratings generated profit

Average Return

-9.38%

reiterated a buy rating 22 days ago

Copying Ryan Daniels's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -9.38% per trade.

2 Years

xxx

Success Rate

2/5 ratings generated profit

Average Return

-9.38%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 40.00% of your transactions generating a profit, with an average return of -9.38% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HNGE Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, HNGE has received 63 Buy Ratings, 25 Hold Ratings, and 0 Sell Ratings. HNGE average Analyst price target in the past 3 months is 59.08.

Each month's total comprises the sum of three months' worth of ratings.

HNGE Financial Forecast

HNGE Earnings Forecast

Next quarter’s earnings estimate for HNGE is $0.38 with a range of $0.27 to $0.43. The previous quarter’s EPS was $0.49. HNGE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year HNGE has Performed in-line its overall industry.

HNGE Sales Forecast

Next quarter’s sales forecast for HNGE is $170.59M with a range of $155.49M to $174.60M. The previous quarter’s sales results were $170.73M. HNGE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year HNGE has Performed in-line its overall industry.

HNGE Stock Forecast FAQ

What is HNGE’s average 12-month price target, according to analysts?

Based on analyst ratings, Hinge Health, Inc. Class A’s 12-month average price target is 59.08.

What is HNGE’s upside potential, based on the analysts’ average price target?

Hinge Health, Inc. Class A has 38.17% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is HNGE a Buy, Sell or Hold?

Hinge Health, Inc. Class A has a consensus rating of Strong Buy which is based on 14 buy ratings, 0 hold ratings and 0 sell ratings.

What is Hinge Health, Inc. Class A’s price target?

The average price target for Hinge Health, Inc. Class A is 59.08. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $72.00 ,the lowest forecast is $50.00. The average price target represents 38.17% Increase from the current price of $42.76.

What do analysts say about Hinge Health, Inc. Class A?

Hinge Health, Inc. Class A’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of HNGE?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Hinge Health, Inc. Class A (HNGE) Stock Forecast & Price Target

HNGE Analyst Ratings

HNGE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Hinge Health, Inc. Class A

HNGE Analyst Recommendation Trends

HNGE Financial Forecast

HNGE Earnings Forecast

HNGE Sales Forecast

HNGE Stock Forecast FAQ

Detailed List of Analyst Forecasts